PRPH : Summary for ProPhase Labs, Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 54 mins

ProPhase Labs, Inc. (PRPH)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.02-0.01 (-0.49%)
At close: 4:00PM EST
People also watch
MSLIRELVPDEXMNOVPSDV
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.03
Open2.03
Bid1.96 x 100
Ask0.00 x
Day's Range1.98 - 2.03
52 Week Range1.08 - 2.45
Volume993
Avg. Volume19,093
Market Cap34.5M
Beta0.43
PE Ratio (TTM)-9.67
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Presslast month

    Pharmaceutical company to sell Cold-Eeze lozenge brand

    DOYLESTOWN, Pa. (AP) — The Pennsylvania-based maker of Cold-Eeze throat lozenges has announced that it has sold the brand to another pharmaceutical company for $50 million.

  • American City Business Journalslast month

    $50M deal: Bucks County firm selling Cold-Eeze brand

    ProPhase Labs Inc. has entered into an agreement to sell its Cold-Eeze cold remedy brand to a wholly owned subsidiary of Mylan N.V. for $50 million. The Philadelphia Business Journals first reported the Doylestown company was exploring the potential sale of the product line in August. The Cold-Eeze brand began as zinc lozenges used to shorten the duration of cold, but the formulations were later expanded to include "Gummies," quick-melts and oral spray versions of the product.

  • TheStreet.comlast month

    Mylan Expands OTC Offerings by Acquiring Cold-Eeze

    Cold-Eeze will become Mylan's largest U.S. over-the-counter brand franchise, and builds upon its $1 billion global OTC business.